Myring (Ethinylestradiol, Etonogestrel)

Ethinylestradiol activates estrogen receptors while etonogestrel binds progesterone receptors. Together they suppress the hypothalamic‑pituitary‑gonadal axis, lowering LH and FSH secretion, which blocks follicular development and ovulation. The progestogen also thickens cervical mucus and modifies the endometrium, creating conditions that impede sperm penetration and implantation.

The prescriber determines the appropriate regimen for each patient. Typically, a single Myring vaginal ring is inserted and left in place for three weeks, followed by a ring‑free week, but exact dosing and duration are individualized based on clinical judgment and patient preference.

Myring is contraindicated during pregnancy because it is designed to prevent conception. For breastfeeding women, limited data exist; most clinicians advise caution during the early postpartum period and recommend discussing alternatives with a healthcare professional.

To request Myring, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India supplies hospitals, pharmacies and procurement teams worldwide, and will ask for trade or institutional credentials. The sales team then replies with pricing, availability, shipping details (including any cold‑chain requirements) and the necessary import documentation.

Myring offers a vaginal delivery system, whereas the most common alternative is the combined oral contraceptive pill. The ring provides steady hormone release, eliminates daily dosing, and may have a lower gastrointestinal side‑effect profile, while oral pills allow more flexible dosing adjustments. Both share similar efficacy and safety considerations.

Myring should be stored at ambient temperature, below 25 °C, in its original sealed packaging. Keep the product away from moisture, direct sunlight, and extreme heat to maintain the integrity of the polymer matrix that controls hormone release.

A healthcare professional or the patient inserts the flexible vaginal ring into the upper vaginal vault using a clean hand. The ring remains in place for three consecutive weeks, after which it is removed and discarded. A new ring is then inserted after a one‑week ring‑free interval.

Serious adverse events include thromboembolic disorders such as deep‑vein thrombosis or pulmonary embolism, cerebrovascular accidents (stroke), myocardial infarction, and severe hepatic complications like hepatic adenoma. Any sudden chest pain, shortness of breath, severe headache, visual changes, or abdominal pain should prompt immediate medical evaluation.

Myring is contraindicated in women with a history of thromboembolic disease, uncontrolled hypertension, known or suspected estrogen‑dependent malignancies, active liver disease, or those who are pregnant. It should also be avoided in smokers over 35 years of age and in individuals taking medications that significantly reduce contraceptive efficacy without appropriate backup methods.